ReviewFrontiers in oncology2025
The role of circulating tumor DNA in gynecological cancer management.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Peri-treatment ctDNA dynamics in locally advanced cervical cancer: pilot study from a safety-net hospital.Gynecologic oncology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer, endometrial cancer, and cervical cancer represent the three most prevalent primary gynecological tumors that pose a significant threat to women's health globally. To enhance survival rates for patients with gynecological cancers, there is an urgent need to optimize disease detection and monitoring technologies aimed at improving early diagnosis, treatment efficacy monitoring, treatment guidance, and prognosis prediction. Currently, traditional methods for identifying and tracking malignant tumors primarily depend on imaging studies, supplemented by blood-based protein biomarker testing. However, these biomarkers generally exhibit limitations in terms of sensitivity and specificity. Circulating tumor DNA (ctDNA), comprising DNA fragments released by cancer cells into the bloodstream, can be detected using liquid biopsy technology. Compared to tissue biopsy, ctDNA testing offers the advantages of minimal invasiveness and continuous monitoring, thereby eliminating the need for multiple surgeries. In addition, it may detect disease recurrence or predict behavior in ways that entity organization biopsy, tumor marker monitoring, and imaging cannot. Increasing evidence indicates that ctDNA has the potential to enhance the clinical management of gynecological tumors by improving early diagnosis, monitoring treatment responses, detecting recurrences, and predicting prognosis. This review aims to summarize the application of ctDNA in gynecological cancers and provide an overview of its comprehensive research and clinical validation. Furthermore, we discuss future development directions based on existing challenges and identify areas requiring further research to elucidate the potential of ctDNA in clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.